deltatrials
Recruiting OBSERVATIONAL NCT06948110

Deciphering the Genetic Architecture of Autoimmune Diseases

Sponsor: National Human Genome Research Institute (NHGRI)

Updated 12 times since 2025 Last updated: Apr 13, 2026 Started: Apr 19, 2026 Primary completion: Apr 22, 2030 Completion: Apr 22, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06948110, this observational or N/A phase trial focuses on Autoimmune Diseases and remains actively recruiting participants. Sponsored by National Human Genome Research Institute (NHGRI), it has been updated 12 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

SUMMARY: The goal of this proposal is to investigate the genomic origins of heterogeneity in both risk and specific phenotype of autoimmune diseases, with a particular emphasis on understanding and addressing the health disparities of these diseases. Autoimmune diseases, especially Systemic Lupus Erythematosus (SLE), manifest at an earlier age and have worse clinical outcomes in individuals of non-European ancestry. Likewise, immunological genetic variants show a differential evolution based on geographical pathogenic pressure; almost 13 percent of loci for SLE, not including human leukocyte antigens (HLA), show signs of natural selection. Therefore, investigating the genomics of autoimmunity globally and in non-European populations is crucial to understanding these observations. The prevalence of autoimmune diseases in Peru is difficult to estimate, since diagnoses require serologies that are not accessible, but it is estimated that there is a large proportion of undiagnosed or untreated cases in the country. Some studies conducted in Latin America and the United States report that the mestizo population presents SLE at an earlier age, with more systemic involvement than European populations. It is necessary to recognize that there is a significant gap in genomic studies conducted in the field of autoimmune diseases, revealing a serious underrepresentation in the indigenous...

SUMMARY:

The goal of this proposal is to investigate the genomic origins of heterogeneity in both risk and specific phenotype of autoimmune diseases, with a particular emphasis on understanding and addressing the health disparities of these diseases. Autoimmune diseases, especially Systemic Lupus Erythematosus (SLE), manifest at an earlier age and have worse clinical outcomes in individuals of non-European ancestry. Likewise, immunological genetic variants show a differential evolution based on geographical pathogenic pressure; almost 13 percent of loci for SLE, not including human leukocyte antigens (HLA), show signs of natural selection. Therefore, investigating the genomics of autoimmunity globally and in non-European populations is crucial to understanding these observations.

The prevalence of autoimmune diseases in Peru is difficult to estimate, since diagnoses require serologies that are not accessible, but it is estimated that there is a large proportion of undiagnosed or untreated cases in the country. Some studies conducted in Latin America and the United States report that the mestizo population presents SLE at an earlier age, with more systemic involvement than European populations. It is necessary to recognize that there is a significant gap in genomic studies conducted in the field of autoimmune diseases, revealing a serious underrepresentation in the indigenous populations of North and South America. In response to this critical need, collaborations have been established between physicians in different areas of Peru and Latin America to study the genomic architecture of autoimmunity in indigenous people in South America, carrying out cutting-edge genomic studies in this under-explored and high-risk population and evaluating population-specific genetic variants that may contribute to the identification of causal genes. including coding or structural changes. We propose to carry out state-of-the-art genomic studies in populations from different areas of Peru (Amazon, Andes, Coast) to describe the genomic architecture in this previously unstudied population.

General Objective:

The general objective of this project is to use genomic strategies to evaluate the molecular basis of human autoimmune diseases, representative of Peruvian populations. Diversification in genomic studies is necessary to reach personalized medicine and collaboration with community leaders and local researchers will ensure community participation and individual engagement, as well as training and education activities.

Specific Objectives:

Specific objective 1: To identify genetic markers associated with genetic risk of autoimmune diseases in the Indigenous population of Peru.

Specific objective 2: To evaluate the integrative multiomics (genomics, epigenomics and exposome) of the environmental context associated with autoimmunity in Peru.

Specific Objective 3: To characterize the microbiome in patients with autoimmunity in Peru.

Primary Endpoint:

Successful recruitment and whole-genome sequencing of at least 20 multiplex families with high familial autoimmunity burden, enabling identification and preliminary annotation of rare or novel genetic variants potentially linked to autoimmune disease susceptibility.

Status Flow

~May 2025 – ~Jun 2025 · 31 days · monthly snapshotRecruiting~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshotRecruiting~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshotRecruiting~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshotRecruiting~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshotRecruiting~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshotRecruiting~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshotRecruiting~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshotRecruiting~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotRecruiting~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshotRecruiting~Mar 2026 – present · 44 days · monthly snapshotRecruitingApr 14, 2026 – present · 1 days · daily APIRecruiting

Change History

12 versions recorded
  1. Apr 14, 2026 — Present [daily]

    Recruiting

  2. Mar 2026 — Present [monthly]

    Recruiting

  3. Feb 2026 — Mar 2026 [monthly]

    Recruiting

  4. Jan 2026 — Feb 2026 [monthly]

    Recruiting

  5. Dec 2025 — Jan 2026 [monthly]

    Recruiting

Show 7 earlier versions
  1. Nov 2025 — Dec 2025 [monthly]

    Recruiting

  2. Oct 2025 — Nov 2025 [monthly]

    Recruiting

  3. Sep 2025 — Oct 2025 [monthly]

    Recruiting

  4. Aug 2025 — Sep 2025 [monthly]

    Recruiting

  5. Jul 2025 — Aug 2025 [monthly]

    Recruiting

  6. Jun 2025 — Jul 2025 [monthly]

    Recruiting

  7. May 2025 — Jun 2025 [monthly]

    Recruiting

    First recorded

Eligibility Summary

Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors. But some diseases behave differently in people who are native to North and South America. Researchers want to know more about the gene changes and other factors that may cause autoimmune diseases among these people. This project will be based in Peru. Objective: To study how gene changes can lead to autoimmune diseases in people native to Peru. Eligibility: People aged 18 years and older with an autoimmune disease. These may include systemic lupus erythematosus; Sjogren disease; scleroderma; rheumatoid arthritis; seronegative spondylo-arthropathies; and systemic vasculitis. Family members and healthy volunteers are also needed. Design: Participants will have 2 clinic visits; these will be 2 weeks apart. The clinics will be in Lima, Iquitos, and other sites in Peru. Visit 1: Participants will have a physical exam. They will answer questions about their health risks and habits. They will provide blood and urine samples. Visit 2: Participants will provide a second blood sample and a stool sample. They will talk about the results of their first clinical exam with researchers. The cost of travel to and from the clinics will be provided. Participants will get $30 per visit and a snack.

Contact Information

Sponsor contact:
  • National Human Genome Research Institute (NHGRI)
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .